NCT03154619View on ClinicalTrials.gov

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

April 4, 2019

Study Completion Date

April 1, 2021

Conditions
Venous Leg Ulcer
Interventions
DRUG

0.1% TR 987

TR 987 0.1%

DRUG

Placebo gel

Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.

Trial Locations (9)

15222

SerenaGroup Research Institute, Pittsburgh

16201

Armstrong County Memorial Hospital, Kittanning

16226

The Foot and Ankle Wellness Center, Ford City

17402

Martin Foot and Ankle, York

33027

Royal Research Corp, Pembroke Pines

33169

Barry University Clinical Research, North Miami Beach

44103

Cleveland Foot and Ankle Clinic, Cleveland

90063

New Hope Podiatry Clinic, Los Angeles

08015

Deborah Heart and Lung Center, Browns Mills

All Listed Sponsors
collaborator

TR Therapeutics

INDUSTRY

lead

SerenaGroup, Inc.

NETWORK